Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Inflammatory Bowel Diseases

  Free Subscription


6 Aliment Pharmacol Ther
3 Am J Gastroenterol
2 Clin Gastroenterol Hepatol
2 Dig Dis Sci
1 Gastroenterol Hepatol
9 Gastroenterology
3 Inflamm Bowel Dis
1 J Clin Gastroenterol
3 J Crohns Colitis
2 Lancet Gastroenterol Hepatol
2 Scand J Gastroenterol
2 Z Gastroenterol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Aliment Pharmacol Ther

  1. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
    The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
    PubMed         Abstract available

  2. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
    PubMed         Abstract available

  3. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
    Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
    PubMed         Abstract available

  4. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
    Comorbidity before and after a diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
    PubMed         Abstract available

  5. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
    Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
    PubMed         Abstract available

  6. KO Y, Paramsothy S, Yau Y, Leong RW, et al
    Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
    PubMed         Abstract available

    Am J Gastroenterol

  7. ABDALLA MI, Levesque BG
    Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.
    Am J Gastroenterol. 2021;116:1187-1188.
    PubMed         Abstract available

  8. HA C
    The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
    Am J Gastroenterol. 2021;116:671-672.
    PubMed         Abstract available

    Do Forgotten Symptoms Need Treatment?
    Am J Gastroenterol. 2021;116:841-842.

    Clin Gastroenterol Hepatol

  10. CASSINOTTI A, Corona A, Duca P, Nebuloni M, et al
    Clin Gastroenterol Hepatol. 2021 Jun 14. pii: S1542-3565(21)00642.
    PubMed         Abstract available

  11. ASSCHER VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, et al
    Deficits in geriatric assessment associate with disease activity and -burden in older patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jun 18. pii: S1542-3565(21)00643.
    PubMed         Abstract available

    Dig Dis Sci

  12. GRANDMOUGIN A, D'Amico F, Remen T, Danese S, et al
    Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease.
    Dig Dis Sci. 2021 Jun 22. pii: 10.1007/s10620-021-07016.
    PubMed         Abstract available

  13. FAWSON S, Dibley L, Smith K, Batista J, et al
    Developing an Online Program for Self-Management of Fatigue, Pain, and Urgency in Inflammatory Bowel Disease: Patients' Needs and Wants.
    Dig Dis Sci. 2021 Jun 19. pii: 10.1007/s10620-021-07109.
    PubMed         Abstract available

    Gastroenterol Hepatol

  14. HIJOS-MALLADA G, Sostres C, Gomollon F
    NSAIDs, gastrointestinal toxicity and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2021 Jun 19. pii: S0210-5705(21)00201.
    PubMed         Abstract available


  15. CASADEI C, Barberio B, Savarino E
    A Peculiar Cutaneous Manifestation in a Patient With Crohn's Disease.
    Gastroenterology. 2021;160:e1-e3.

  16. SAZONOVS A, Ahmad T, Anderson CA
    Underpowered PANTS: A Response to the Conclusions of "Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab".
    Gastroenterology. 2021;160:470-471.

  17. NORSA L, D'Antiga L
    Gastroenterology. 2021;160:474-475.

  18. KELLERMAYER R, van der Laan M
    Validation of Predictive Models in Inflammatory Bowel Diseases.
    Gastroenterology. 2021;160:21-22.

  19. LEE M, Chang EB
    Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues.
    Gastroenterology. 2021;160:524-537.
    PubMed         Abstract available

  20. MAHMUD N, Weiss A, Trivedi C, Yang YX, et al
    Risk of Venous Thromboembolism among Inflammatory Bowel Disease patients who contract SARS-CoV-2.
    Gastroenterology. 2021 Jun 14. pii: S0016-5085(21)03123.

  21. HADI YB, Thakkar S, Shah-Khan SM, Hutson W, et al
    COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: Analysis of a large multi-institutional research network in United States.
    Gastroenterology. 2021 Jun 15. pii: S0016-5085(21)03125.

  22. PEYRIN-BIROULET L, Loftus EV Jr, Colombel JF, Danese S, et al
    Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY.
    Gastroenterology. 2021 Jun 15. pii: S0016-5085(21)03126.
    PubMed         Abstract available

  23. BAUMGARTNER M, Lang M, Holley H, Crepaz D, et al
    Mucosal biofilms are an endoscopic feature of irritable bowel syndrome and ulcerative colitis.
    Gastroenterology. 2021 Jun 16. pii: S0016-5085(21)03138.
    PubMed         Abstract available

    Inflamm Bowel Dis

  24. CHOSHEN S, Turner D, Pratt LT, Precel R, et al
    Development and Validation of a Pediatric MRI-Based Perianal Crohn Disease (PEMPAC) Index-A Report from the ImageKids Study.
    Inflamm Bowel Dis. 2021 Jun 21. pii: 6307118. doi: 10.1093.
    PubMed         Abstract available

  25. TAFT TH, Quinton S, Jedel S, Simons M, et al
    Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes.
    Inflamm Bowel Dis. 2021 Jun 17. pii: 6301664. doi: 10.1093.
    PubMed         Abstract available

  26. HANZEL J, Dreesen E, Vermeire S, Lowenberg M, et al
    Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study.
    Inflamm Bowel Dis. 2021 Jun 17. pii: 6301858. doi: 10.1093.
    PubMed         Abstract available

    J Clin Gastroenterol

  27. MORTENSEN JH, van Haaften WT, Karsdal MA, Bay-Jensen AC, et al
    The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFalpha Treatment in Crohn's Disease.
    J Clin Gastroenterol. 2021;55:59-66.
    PubMed         Abstract available

    J Crohns Colitis

  28. GIANOTTI RJ, Cheifetz AS
    Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?
    J Crohns Colitis. 2021 Jun 17. pii: 6301791. doi: 10.1093.

  29. KIM PH, Yoon HM, Jung AY, Lee JS, et al
    Diagnostic Performance of Diffusion-weighted Imaging for Evaluation of Bowel Inflammation in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308099. doi: 10.1093.
    PubMed         Abstract available

  30. GILMORE R, Hilley P, Srinivasan A, Choy M, et al
    Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308093. doi: 10.1093.
    PubMed         Abstract available

    Lancet Gastroenterol Hepatol

  31. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    PubMed         Abstract available

  32. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.

    Scand J Gastroenterol

  33. KRISTENSEN VA, Opheim R, Perminow G, Huppertz-Hauss G, et al
    Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway.
    Scand J Gastroenterol. 2021 Jun 21:1-7. doi: 10.1080/00365521.2021.1922746.
    PubMed         Abstract available

  34. KOLEHMAINEN S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, et al
    Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
    Scand J Gastroenterol. 2021 Jun 21:1-8. doi: 10.1080/00365521.2021.1938206.
    PubMed         Abstract available

    Z Gastroenterol

  35. NEUFELD T, Pfuhlmann K, Stock-Schroer B, Kairey L, et al
    Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey.
    Z Gastroenterol. 2021 Jun 22. doi: 10.1055/a-1400-2768.
    PubMed         Abstract available

    Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations.
    Z Gastroenterol. 2021 Jun 23. doi: 10.1055/a-1482-9273.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.